{
  "id": "61f609d3882a024a10000024",
  "type": "factoid",
  "question": "Bimekizumab is used for treatment of which disease?",
  "ideal_answer": "Bimekizumab is used for psoriasis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34623614",
    "http://www.ncbi.nlm.nih.gov/pubmed/33727793",
    "http://www.ncbi.nlm.nih.gov/pubmed/34260044",
    "http://www.ncbi.nlm.nih.gov/pubmed/27859546",
    "http://www.ncbi.nlm.nih.gov/pubmed/31214486",
    "http://www.ncbi.nlm.nih.gov/pubmed/34471992",
    "http://www.ncbi.nlm.nih.gov/pubmed/34687214",
    "http://www.ncbi.nlm.nih.gov/pubmed/34077151",
    "http://www.ncbi.nlm.nih.gov/pubmed/30332893",
    "http://www.ncbi.nlm.nih.gov/pubmed/33549193",
    "http://www.ncbi.nlm.nih.gov/pubmed/34408825",
    "http://www.ncbi.nlm.nih.gov/pubmed/34178093",
    "http://www.ncbi.nlm.nih.gov/pubmed/33026212",
    "http://www.ncbi.nlm.nih.gov/pubmed/31172372",
    "http://www.ncbi.nlm.nih.gov/pubmed/34384327"
  ],
  "snippets": [
    {
      "text": "In BE RADIANT, patients were randomised 1:1 to bimekizumab 320\u00a0mg every 4\u00a0weeks (Q4W) or secukinumab 300\u00a0mg (weekly until Week 4, then Q4W). Three items (itching, skin pain and scaling) of the P-SIM were electronically assessed throughout the trial and were scored from 0 to 10 (none to very severe signs/symptoms/impacts).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34471992",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: In this review, we include a study of the new anti-IL-17 biological agents (secukinumab, ixekizumab, and bromalizumab) used for moderate-to-severe psoriasis and psoriatic arthritis treatment in clinical practice, as well as pivotal trials with bimekizumab. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33026212",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bimekizumab: the new drug in the biologics armamentarium for psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34178093",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Due to its novel mechanism of action (dual inhibition of IL-17A and IL-17F), bimekizumab is considered a new therapeutic approach for the treatment of moderate-to-severe psoriasis. Bimekizumab has demonstrated superiority in all direct comparative clinical trials conducted, whether against ustekinumab (IL-12/23 inhibitor), adalimumab (TNF inhibitor) or secukinumab (IL-17A inhibitor), and has shown very encouraging results for the treatment of psoriatic arthritis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34178093",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: Plaque psoriasis can significantly impact patients' quality of life. We assessed psychometric properties of the Psoriasis Symptoms and Impacts Measure (P-SIM), developed to capture patients' experiences of signs, symptoms and impacts of psoriasis.METHODS: Pooled, blinded, 16-week data from 1002 patients in the BE\u00a0VIVID and BE\u00a0READY bimekizumab phase\u00a03 trials were analysed. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34260044",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bimekizumab for the treatment of psoriatic disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30332893",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " of action (dual inhibition of IL-17A and IL-17F), bimekizumab is considered a new therapeutic approach for the treatment of moderate-to-severe psoriasis. Bimekizumab has demonstra",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34178093",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31172372",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Here we will discuss the safety and efficacy of bimekizumab in the treatment of moderate-to-severe plaque psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34077151",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33727793",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Long-term results and head-to-head trials comparing bimekizumab with other agents will be crucial to define the role of bimekizumab in the treatment of psoriatic disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31172372",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Bimekizumab is a monoclonal antibody that selectively inhibits both IL-17A and IL-17F, currently under investigation for moderate to severe plaque psoriasis. Maintenance dosing every 4 weeks is",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34687214",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27859546",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "igen-binding site of bimekizumab neutralizes both IL-17A and IL-17F; phase I, II, and III studies have demonstrated its efficacy and safety in psoriasis and psoriatic arthritis. Sonelok",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34408825",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "de alone. Bimekizumab is the first human monoclonal antibody to exert simultaneous specific inhibition of IL-17A and IL-17\u00a0F, and has been studied in several phase II/III trials for psoriasi",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34384327",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34384327",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Bimekizumab for Moderate-to-Severe Plaque Psoriasis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34077151",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Bimekizumab for the Treatment of Psoriasis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34623614",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33549193",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Bimekizumab for the Treatment of Psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34623614",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31214486",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Bimekizumab for Moderate-to-Severe Plaque Psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34077151",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Bimekizumab is currently in clinical development for psoriasis, psoriatic arthritis, and ankylosing spondylitis, with promising results.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31172372",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ockade alone. Bimekizumab is the first human monoclonal antibody to exert simultaneous specific inhibition of IL-17A and IL-17\u00a0F, and has been studied in several phase II/III trials for psoriasis and PsA.AREAS COVERED: Bimekizumab is no",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34384327",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "psoriasis"
}